Rheumatoid Arthritis Market is Projected to Grow Significantly by 2036 Owing to the Rising Geriatric Population and Advancements in Novel Immunomodulatory Therapies | DelveInsight

The market dynamics for Rheumatoid Arthritis are witnessing steady growth driven by the increasing prevalence of autoimmune disorders, rising geriatric population, growing demand for targeted biologics and oral therapies, and continuous advancements in immunomodulatory treatments. Additionally, the launch of emerging therapies such as LNK01001 (Lynk Pharmaceuticals), AP1189/Resomelagon (SynAct Pharma), Ocadusertib (Eli Lilly and Company), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Rheumatoid Arthritis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Rheumatoid Arthritis Market
• The market size for Rheumatoid Arthritis in the leading markets is expected to grow significantly by 2036.
• The United States accounted for the highest Rheumatoid Arthritis treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• The worldwide prevalence of Rheumatoid Arthritis is approximately 0.24%, highlighting the significant global burden of the disease.
• The annual incidence of Rheumatoid Arthritis in the United States and other western nations of northern Europe is approximately 40 per 100,000 persons.
• Growing awareness regarding autoimmune disorders and advancements in diagnostic approaches are improving early diagnosis and treatment initiation for Rheumatoid Arthritis patients globally.
• Leading Rheumatoid Arthritis companies, such as Lynk Pharmaceuticals, SynAct Pharma, Eli Lilly and Company, DeepCure, Sonoma Biotherapeutics, Rise Therapeutics, and others, are developing new Rheumatoid Arthritis treatment drugs that can be available in the Rheumatoid Arthritis market in the coming years.
• The promising Rheumatoid Arthritis therapies in clinical trials include LNK01001, AP1189 (Resomelagon), Ocadusertib, DC-9476, R-2487, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Rheumatoid Arthritis Market
• Growing Geriatric Population: Rheumatoid Arthritis incidence increases with age, and with the global population aging, especially in high-income and emerging countries, the number of people at risk is rising. Older adults are more likely to seek treatment due to pain and mobility issues that affect quality of life, thereby boosting demand for long-term Rheumatoid Arthritis therapies.
• Ongoing Clinical Research and Pipeline Development: The Rheumatoid Arthritis pipeline is rich with promising candidates including next-generation Janus kinase inhibitors, immunomodulators, TNF inhibitors, and novel oral agents. Pharmaceutical companies are investing heavily in research and development to develop safer and more effective therapies with fewer side effects.
• Increasing Demand for Advanced and Personalized Therapies: Current treatment approaches increasingly focus on biologics, DMARDs, targeted oral therapies, and precision medicine approaches aimed at improving disease remission and patient quality of life.

Rheumatoid Arthritis Competitive Landscape
• Several Rheumatoid Arthritis drugs in development include LNK01001 (Lynk Pharmaceuticals), AP1189/Resomelagon (SynAct Pharma), Ocadusertib (Eli Lilly and Company), DC-9476 (DeepCure), and R-2487 (Rise Therapeutics).
• These candidates target diverse mechanisms such as Janus kinase 1 inhibition, melanocortin receptor agonism, TNF inhibition, BRD4 protein inhibition, and immunomodulatory pathways, aiming to improve efficacy, safety, and long-term disease management outcomes in Rheumatoid Arthritis patients.

Discover more about therapies set to grab major Rheumatoid Arthritis market share @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Rheumatoid Arthritis Market
• In January 2026, Lynk Pharmaceuticals Co., Ltd. announced positive topline results from its Phase III clinical trial evaluating zemprocitinib (LNK01001) in patients with moderate to severe active Rheumatoid Arthritis. The study demonstrated statistically significant improvements versus placebo with a favorable safety and tolerability profile.
• In February 2026, SynAct Pharma announced that it successfully reached the recruitment goal of 240 randomized subjects in the 12-week Phase IIb ADVANCE study of resomelagon in newly diagnosed Rheumatoid Arthritis patients.
• In November 2025, SynAct Pharma announced that 190 out of 240 patients had been randomized in the Phase IIb ADVANCE study evaluating AP1189 (Resomelagon) in Rheumatoid Arthritis.
• In October 2025, RheumaGen and SiVEC Biotechnologies announced a licensing and joint development agreement for gene-editing therapies designed to treat autoimmune diseases including Rheumatoid Arthritis.
• In August 2024, DeepCure announced a collaboration with the Leeds Institute of Rheumatic and Musculoskeletal Medicine to investigate DC-9476 as a potential treatment for Rheumatoid Arthritis patients with inadequate response to current standard therapies.

What is Rheumatoid Arthritis?
Rheumatoid Arthritis (RA) is an autoimmune disorder of the joints characterized by inflammatory arthritis as well as extra-articular involvement. It commonly affects multiple joints, especially the small joints of the hands and wrists, leading to pain, swelling, stiffness, and progressive joint damage. Rheumatoid Arthritis is associated with immune-mediated inflammation involving anti-citrullinated protein antibodies (ACPA), cytokine activation, and chronic synovial inflammation. Although there is no cure for Rheumatoid Arthritis, current therapies including DMARDs, biologics, and targeted therapies help control symptoms, improve quality of life, and reduce disease progression.

Rheumatoid Arthritis Epidemiology Segmentation
The Rheumatoid Arthritis epidemiology section provides insights into the historical and current Rheumatoid Arthritis patient pool and forecasted trends for the leading markets. The Rheumatoid Arthritis market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
• Total Prevalent Cases of Rheumatoid Arthritis
• Gender-specific Cases of Rheumatoid Arthritis
• Age-specific Cases of Rheumatoid Arthritis
• Severity-specific Cases of Rheumatoid Arthritis
• Diagnosed and Treated Cases of Rheumatoid Arthritis

Scope of the Rheumatoid Arthritis Market Report
• Therapeutic Assessment: Rheumatoid Arthritis current marketed and emerging therapies
• Rheumatoid Arthritis Market Dynamics: Key Market Forecast Assumptions of Emerging Rheumatoid Arthritis Drugs and Market Outlook
• Key Companies: Lynk Pharmaceuticals, SynAct Pharma, Eli Lilly and Company, DeepCure, Sonoma Biotherapeutics, Rise Therapeutics, and others
• Key Therapies: LNK01001, AP1189 (Resomelagon), Ocadusertib, DC-9476, R-2487, Methotrexate, Leflunomide, Hydroxychloroquine, Sulfasalazine, and others
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement

To know more about Rheumatoid Arthritis companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Rheumatoid Arthritis Market Report Introduction
2. Executive Summary for Rheumatoid Arthritis
3. SWOT Analysis of Rheumatoid Arthritis
4. Rheumatoid Arthritis Patient Share (%) Overview at a Glance
5. Rheumatoid Arthritis Market Overview at a Glance
6. Rheumatoid Arthritis Background and Overview
7. Rheumatoid Arthritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Rheumatoid Arthritis
9. Rheumatoid Arthritis Current Treatment and Medical Practices
10. Rheumatoid Arthritis Unmet Needs
11. Rheumatoid Arthritis Emerging Therapies
12. Rheumatoid Arthritis Market Outlook
13. Country-Wise Rheumatoid Arthritis Market Analysis (2022-2036)
14. Rheumatoid Arthritis Market Access and Reimbursement of Therapies
15. Rheumatoid Arthritis Market Drivers
16. Rheumatoid Arthritis Market Barriers
17. Rheumatoid Arthritis Appendix
18. Rheumatoid Arthritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.